Oncogenic features of neuromedin U in breast cancer are associated with NMUR2 expression involving crosstalk with members of the WNT signaling pathway

Neuromedin U (NMU) has been shown driving the progression of various tumor entities, including breast cancer. However, the expression pattern of NMU and its receptors in breast cancer tissues as well as systematic insight into mechanisms and downstream targets of the NMU-driven signaling pathways are still elusive. Here, NMU expression was found up-regulated in all breast cancer subtypes when compared to healthy breast tissue. Using an in silico dataset comprising 1,195 samples, high NMU expression was identified as an indicator of poor outcome in breast tumors showing strong NMUR2 expression. Next, the biological impact of NMU on breast cancer cells in relation to NMUR2 expression was analyzed. Ectopic NMU expression reduced colony growth while promoting a motile phenotype in NMUR2-positive SKBR3 but not NMUR2-negative Hs578T cells. To uncover signaling pathways and key molecules affected by NMU in SKBR3 cells, Affymetrix microarray analysis was applied. Forced NMU expression affected molecules involved in WNT receptor signaling among others. As such we demonstrated enhanced activation of the WNT/planar cell polarity (PCP) effector RAC1 and down-regulation of canonical WNT targets such as MYC. In summary, NMU might contribute to progression of NMUR2-positive breast cancer representing a potential druggable target for future personalized strategies.

[1]  Zhongyou Li,et al.  NMU signaling promotes endometrial cancer cell progression by modulating adhesion signaling , 2016, Oncotarget.

[2]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[3]  W. Dreher,et al.  Short-Term Cuprizone Feeding Verifies N-Acetylaspartate Quantification as a Marker of Neurodegeneration , 2015, Journal of Molecular Neuroscience.

[4]  P. Bragado,et al.  Mechanisms of disseminated cancer cell dormancy: an awakening field , 2014, Nature Reviews Cancer.

[5]  L. O’Driscoll,et al.  Neuromedin U: a candidate biomarker and therapeutic target to predict and overcome resistance to HER-tyrosine kinase inhibitors. , 2014, Cancer research.

[6]  Hyun-Joo Park,et al.  Hypoxia Regulates the Expression of the Neuromedin B Receptor through a Mechanism Dependent on Hypoxia-Inducible Factor-1α , 2013, PloS one.

[7]  P. Morgan,et al.  Neuromedin U Partly Mimics Thyroid-Stimulating Hormone and Triggers Wnt/β-Catenin Signalling in the Photoperiodic Response of F344 Rats , 2013, Journal of neuroendocrinology.

[8]  Jun Du,et al.  Rab35 is required for Wnt5a/Dvl2-induced Rac1 activation and cell migration in MCF-7 breast cancer cells. , 2013, Cellular signalling.

[9]  S Michiels,et al.  Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group Statement. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Chris T. A. Evelo,et al.  Bioinformatics Applications Note Databases and Ontologies Go-elite: a Flexible Solution for Pathway and Ontology Over-representation , 2022 .

[11]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[12]  D. Radisky,et al.  MYC Suppresses Cancer Metastasis by Direct Transcriptional Silencing of αv and β3 Integrin Subunits , 2012, Nature Cell Biology.

[13]  Yuan Zhang,et al.  Neuromedin U Type 1 Receptor Stimulation of A-type K+ Current Requires the βγ Subunits of Go Protein, Protein Kinase A, and Extracellular Signal-regulated Kinase 1/2 (ERK1/2) in Sensory Neurons* , 2012, The Journal of Biological Chemistry.

[14]  M. Ashcroft,et al.  Inactivation of the von Hippel-Lindau tumour suppressor gene induces Neuromedin U expression in renal cancer cells , 2011, Molecular Cancer.

[15]  Holger Sültmann,et al.  The anterior gradient 2 (AGR2) gene is overexpressed in prostate cancer and may be useful as a urine sediment marker for prostate cancer detection , 2011, The Prostate.

[16]  Dorothea Emig,et al.  AltAnalyze and DomainGraph: analyzing and visualizing exon expression data , 2010, Nucleic Acids Res..

[17]  A. Schally,et al.  Targeting gastrin releasing peptide receptors: New options for the therapy and diagnosis of cancer. , 2010, Cell cycle.

[18]  N. Hynes,et al.  Key signalling nodes in mammary gland development and cancer: Myc , 2009, Breast Cancer Research.

[19]  J. Maguire,et al.  Emerging pharmacology and physiology of neuromedin U and the structurally related peptide neuromedin S , 2009, British journal of pharmacology.

[20]  E. Dahl,et al.  Expression of the glioma-associated oncogene homolog (GLI) 1 in human breast cancer is associated with unfavourable overall survival , 2009, BMC Cancer.

[21]  G. Hortobagyi,et al.  Breast cancer metastasis: challenges and opportunities. , 2009, Cancer research.

[22]  J. Hoheisel,et al.  Neuromedin U is overexpressed in pancreatic cancer and increases invasiveness via the hepatocyte growth factor c-Met pathway. , 2009, Cancer letters.

[23]  T. Triche,et al.  Translational activation of snail1 and other developmentally regulated transcription factors by YB-1 promotes an epithelial-mesenchymal transition. , 2009, Cancer cell.

[24]  R. Serra,et al.  Loss of TGF-β or Wnt5a results in an increase in Wnt/β-catenin activity and redirects mammary tumour phenotype , 2009, Breast Cancer Research.

[25]  Alan Hall,et al.  Wnt signaling pathways meet Rho GTPases. , 2009, Genes & development.

[26]  Tatyana Chernova,et al.  Direct repression of cyclin D1 by SIP1 attenuates cell cycle progression in cells undergoing an epithelial mesenchymal transition. , 2007, Molecular biology of the cell.

[27]  Takahiro Matsumoto,et al.  Central control of bone remodeling by neuromedin U , 2007, Nature Medicine.

[28]  H. Frierson,et al.  Neuromedin U is regulated by the metastasis suppressor RhoGDI2 and is a novel promoter of tumor formation, lung metastasis and cancer cachexia , 2007, Oncogene.

[29]  T. Schlange,et al.  Novel c‐MYC target genes mediate differential effects on cell proliferation and migration , 2007, EMBO reports.

[30]  T. Asahara,et al.  Expression of Wnt-5a is correlated with aggressiveness of gastric cancer by stimulating cell migration and invasion. , 2006, Cancer research.

[31]  Yusuke Nakamura,et al.  The neuromedin U-growth hormone secretagogue receptor 1b/neurotensin receptor 1 oncogenic signaling pathway as a therapeutic target for lung cancer. , 2006, Cancer research.

[32]  N. Shankley,et al.  Neuromedin U stimulates contraction of human long saphenous vein and gastrointestinal smooth muscle in vitro , 2006, Regulatory Peptides.

[33]  J. Paulus,et al.  G1/S Cell Cycle Arrest Provides Anoikis Resistance through Erk-Mediated Bim Suppression , 2005, Molecular and Cellular Biology.

[34]  K. Pantel,et al.  Circulating Tumor Cells in Breast Cancer: Correlation to Bone Marrow Micrometastases, Heterogeneous Response to Systemic Therapy and Low Proliferative Activity , 2005, Clinical Cancer Research.

[35]  T. Kowalski,et al.  Transgenic overexpression of neuromedin U promotes leanness and hypophagia in mice. , 2005, The Journal of endocrinology.

[36]  P. Szekeres,et al.  Neuromedin U and Its Receptors: Structure, Function, and Physiological Roles , 2004, Pharmacological Reviews.

[37]  K. Kangawa,et al.  The gut-brain peptide neuromedin U is involved in the mammalian circadian oscillator system. , 2004, Biochemical and biophysical research communications.

[38]  A. Dray,et al.  Pro-nociceptive effects of neuromedin u in rat , 2003, Neuroscience.

[39]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[40]  B. Borowsky,et al.  Identification and Characterization of Two Neuromedin U Receptors Differentially Expressed in Peripheral Tissues and the Central Nervous System* , 2000, The Journal of Biological Chemistry.

[41]  F. Monsma,et al.  Identification of a human gastrointestinal tract and immune system receptor for the peptide neuromedin U. , 2000, Molecular pharmacology.

[42]  J. Chambers,et al.  Neuromedin U Is a Potent Agonist at the Orphan G Protein-coupled Receptor FM3* , 2000, The Journal of Biological Chemistry.

[43]  Christopher P. Austin,et al.  Identification of receptors for neuromedin U and its role in feeding , 2000, Nature.

[44]  D. Carter.  TNM Classification of Malignant Tumors , 1998 .

[45]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[46]  S. Bloom,et al.  Cloning and characterization of the cDNA encoding the human neuromedin U (NmU) precursor: NmU expression in the human gastrointestinal tract. , 1995, Journal of molecular endocrinology.

[47]  I. Ellis,et al.  Method for grading breast cancer. , 1993, Journal of clinical pathology.

[48]  W. Remmele,et al.  [Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical estrogen receptor detection (ER-ICA) in breast cancer tissue]. , 1987, Der Pathologe.

[49]  N. Minamino,et al.  Neuromedin U-8 and U-25: novel uterus stimulating and hypertensive peptides identified in porcine spinal cord. , 1985, Biochemical and biophysical research communications.

[50]  Steven J. M. Jones,et al.  Comprehensive molecular portraits of human breast tumours , 2013 .

[51]  Baljit Singh,et al.  Oncogenic beta-catenin is required for bone morphogenetic protein 4 expression in human cancer cells. , 2002, Cancer research.

[52]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.